18:26 , Nov 7, 2018 |  BioCentury  |  Emerging Company Profile

ABL bispecifics

Korean biotech ABL Bio Inc. is developing bispecifics for cancer and Parkinson’s disease, and has evidence suggesting its lead candidate against VEGF and DLL4 is more potent than at least one of its Western competitors....
16:33 , Jun 20, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Stroke Cell culture and mouse studies suggest HMGB1 could help treat white matter stroke. In oxygen- and glucose-deprived primary mouse oligodendrocytes, HMGB1 levels were higher than in oligodendrocytes cultured in normal conditions, and in...
23:34 , Jun 15, 2017 |  BC Innovations  |  Tools & Techniques

Breaking the barrier

A three-way deal between Amgen Inc. , Feldan Therapeutics Inc. and Elasmogen Ltd. is the latest cause for optimism that technologies are finally converging to enable the generation of cell-penetrating biologics. The biotechs join a...
15:57 , Jun 7, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer...
17:56 , Jan 4, 2017 |  BC Innovations  |  Emerging Company Profile

Orum’s forum

  A major downside of therapeutic antibodies is that they can’t touch intracellular targets: the biologics are too large to diffuse across cell membranes on their own, and those entering cells via endocytosis degrade before...
19:12 , Dec 15, 2016 |  BC Innovations  |  Product R&D

p53 and Ras: Back from the dead

After decades of research and countless failed attempts at drug development, industry is reviving its interest in two of oncology’s most intractable targets, p53 and Ras. While no one denies there’s still a long road...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Company News

Ajou University, MiracleIN deal

MiracleIN and the university’s college of pharmacy partnered to develop drugs to prevent infectious diseases, including swine-origin influenza and Middle East respiratory syndrome (MERS). Ajou will seek regulatory approval in Korea and then in the...
07:00 , Jun 3, 2010 |  BC Innovations  |  Cover Story

HIF2A: mastering osteoarthritis

Most approved osteoarthritis therapies treat symptoms of the disease but not the underlying processes that lead to cartilage destruction and bone spur formation in joints. Now, separate research teams from Japan and South Korea have...